Vertosa, a science-first cannabis company that creates the most effective and reliable active ingredients for infused products, announced the United States patent for one of its core emulsion formulas. Validated by more than two years of use in the market, the now patented formula is part of a growing portfolio of intellectual property for Vertosa and its brand partners. In addition, Vertosa, in partnership with Emery Pharma, an accredited third-party full-service contract research laboratory, will conduct a series of Pharmacokinetic (PK) studies that explore the bioavailability of emulsified CBD, THC, and other compounds derived from the cannabis plant with a specific focus on the efficacy of various product formats made with cannabis distillate versus cannabis emulsion. The CBD study results will be published this summer. As cannabis legalization expands worldwide, and influential markets like New York emerge, Vertosa’s patented technology and pharmaceutical knowledge will help an even broader range of companies achieve a targeted experience for consumers and accelerate products to market.

Mmp News Author, Medical Marijuana Program Connection, 07/29/2021 21:46:00

Open article: